As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > COMMENTARY
COMMENTARY
-
COMMENTARY/Why Does the Use of Generics Not Increase?
April 27, 2009
-
EMTs Allowed to Administer Epipen
April 27, 2009
-
COMMENTARY/Medway Data Falsification to Make Blood Product Self-Sufficiency Difficult
April 20, 2009
-
The First Round Results of GE Amlodipine (2)- Making No Surprise Moves Leads to Success -
April 6, 2009
-
COMMENTARY/Worst Scenario Coming True due to Heated Competition among Wholesalers
March 23, 2009
-
Unexpected Demand for ActHIB Causes Shortage of Supply
March 16, 2009
-
COMMENTARY/Aggressive Overseas Investments Affect Business of Top-4 Pharmas
February 23, 2009
-
COMMENTARY/National Consensus Needed to Balance Soaring Costs of New Drugs against Their Benefits
February 16, 2009
-
Majority of People Have Misconceptions about Antibacterials: Pfizer Survey
February 9, 2009
-
Patent Expiration of Blockbusters and New Breakthrough Candidates from Japanese Pharmaceutical Companies
February 9, 2009
-
Paltac/Alfresa Merger Plan Canceled, but Distribution Reform Remains to Be Done
February 2, 2009
-
COMMENTARY/Industry Should Guarantee Development of Innovative Drugs and Use of More Generics
January 19, 2009
-
COMMENTARY/Aiming at Further Growth beyond Global Recession
January 12, 2009
-
COMMENTARY/Rule to Restrict Participation in CDFS Committee Deliberations Needs Continued Validation
January 5, 2009
-
COMMENTARY/Will Economic Incentives for Med. Institutions Be Effective to Promote Use of Generics?
December 22, 2008
-
Commentary/Issue of Online Sales of OTC Drugs at Standstill
December 15, 2008
-
COMMENTARY/Toyota, NEC Start Direct Inspection, Payment of Medical Bills
December 8, 2008
-
COMMENTARY/Will VITAL KSK Become Core of Alliance of Regional Wholesalers?
December 8, 2008
-
SURVEY/DPP-4 Inhibitors May Decrease Consumption of SUs
December 1, 2008
-
COMMENTARY/Thinking about Why Megapharmas Are Closing Research Labs in Japan
November 24, 2008
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…